Google
LIXT — LIXTE BIOTECHNOLOGY HOLDINGS INC (Healthcare >> Biotechnology)
LIXT FAQ
What is LIXT's ROE?
LIXTE BIOTECHNOLOGY HOLDINGS INC reports a Return on Equity (ROE) of -91.55%.
What is LIXT's dividend yield?
LIXTE BIOTECHNOLOGY HOLDINGS INC offers a dividend yield of 0.00%.
What is LIXT's Deepscope Quality Score?
Deepscope rates LIXT's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy LIXT?
Deepscope's AI Timing Score for LIXT is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does LIXT belong to?
LIXTE BIOTECHNOLOGY HOLDINGS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 7.00
Price
0.29
(4.32%)
Day Change
|
|
|---|
LIXT, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 66 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 7.00 |
| PBV / Sector |
9.05 / 4.58
|
| Earning Per Share | -0.61 |
| PE / Sector |
N/A / 17.10
|
| PEG or PE/Growth / Sector |
N/A / 0.52
|
| Average 1M Daily Value |
1.03 M
GREAT
|
| Average 1W Daily Value |
2.23 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-05 09:12:03 |
| Symbol | LIXT |
| Name | LIXTE BIOTECHNOLOGY HOLDINGS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 12.38 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 83.09 / 8,655.90 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 433 Plaza Real, Boca Raton, FL, United States, 33432
Phone: 631 830 7092
Website: https://lixte.com
Sector: Healthcare >> Biotechnology
Description: Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical and proton cancer therapy company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Boca Raton, Florida.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
